Zydus Lifesciences Limited (NSE:ZYDUSLIFE) — Market Cap & Net Worth
Market Cap & Net Worth: Zydus Lifesciences Limited (ZYDUSLIFE)
Zydus Lifesciences Limited (NSE:ZYDUSLIFE) has a market capitalization of $12.02 Billion (Rs1.11 Trillion) as of June 15, 2026. Listed on the NSE stock exchange, this India-based company holds position #1961 globally and #74 in its home market, demonstrating a 1.85% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zydus Lifesciences Limited's stock price Rs1104.70 by its total outstanding shares 1006233990 (1.01 Billion). Review ZYDUSLIFE current and long-term liabilities to assess the company's total debt and financial obligations.
Zydus Lifesciences Limited Market Cap History: 2015 to 2026
Zydus Lifesciences Limited's market capitalization history from 2015 to 2026. Data shows growth from $3.29 Billion to $12.02 Billion (9.99% CAGR).
Index Memberships
Zydus Lifesciences Limited is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY HEALTHCARE
NIFTYHEALTHCARE
|
$111.47 Billion | 10.78% | #4 of 20 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$3.15 Trillion | 0.38% | #69 of 750 |
Weight: Zydus Lifesciences Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Zydus Lifesciences Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zydus Lifesciences Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.04x
Zydus Lifesciences Limited's market cap is 0.04 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.22x
Zydus Lifesciences Limited's market cap is 0.22 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.61 Billion | $94.27 Billion | $19.34 Billion | 0.04x | 0.19x |
| 2017 | $4.45 Billion | $93.77 Billion | $14.88 Billion | 0.05x | 0.30x |
| 2018 | $3.60 Billion | $119.05 Billion | $17.76 Billion | 0.03x | 0.20x |
| 2019 | $2.66 Billion | $131.66 Billion | $18.49 Billion | 0.02x | 0.14x |
| 2020 | $5.06 Billion | $142.53 Billion | $11.77 Billion | 0.04x | 0.43x |
| 2021 | $5.16 Billion | $144.03 Billion | $21.34 Billion | 0.04x | 0.24x |
| 2022 | $4.51 Billion | $151.10 Billion | $44.87 Billion | 0.03x | 0.10x |
| 2023 | $7.48 Billion | $172.37 Billion | $19.60 Billion | 0.04x | 0.38x |
| 2024 | $10.57 Billion | $195.47 Billion | $38.59 Billion | 0.05x | 0.27x |
| 2025 | $9.95 Billion | $232.41 Billion | $45.26 Billion | 0.04x | 0.22x |
Competitor Companies of ZYDUSLIFE by Market Capitalization
Companies near Zydus Lifesciences Limited in the global market cap rankings as of June 15, 2026.
Key companies related to Zydus Lifesciences Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #509 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #553 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #598 globally with a market cap of $45.26 Billion USD ( CN¥309.32 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #626 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #509 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #553 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.31 |
| #598 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.26 Billion | CN¥48.49 |
| #626 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
Zydus Lifesciences Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Zydus Lifesciences Limited's market cap moved from $3.29 Billion to $ 12.02 Billion, with a yearly change of 9.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs12.02 Billion | +20.82% |
| 2025 | Rs9.95 Billion | -5.90% |
| 2024 | Rs10.57 Billion | +41.44% |
| 2023 | Rs7.48 Billion | +65.58% |
| 2022 | Rs4.51 Billion | -12.46% |
| 2021 | Rs5.16 Billion | +1.92% |
| 2020 | Rs5.06 Billion | +90.20% |
| 2019 | Rs2.66 Billion | -26.06% |
| 2018 | Rs3.60 Billion | -19.09% |
| 2017 | Rs4.45 Billion | +23.32% |
| 2016 | Rs3.61 Billion | +9.63% |
| 2015 | Rs3.29 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 15th, 2026 the market cap of Zydus Lifesciences Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.02 Billion USD |
| MoneyControl | $12.02 Billion USD |
| MarketWatch | $12.02 Billion USD |
| marketcap.company | $12.02 Billion USD |
| Reuters | $12.02 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zydus Lifesciences Limited
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, con… Read more